A home-grown leader in sleep and neural analysis, Compumedics is tackling the burgeoning US home sleep testing market.

It's a subdued start to trading with tariff talk dampening US markets. Pharmaceutical and Energy stocks are the unlucky casualties today.

The PlayStation 5 consoles are made in China, which remain subject to Mr Trump’s bruising tariffs, with Beijing and the White ...

Guy Le Page looks at Cygnus Metals and its big plans to build out a high-grade copper-gold opportunity through additional discoveries.

Canaccord's Tim Hoff saw Azure Minerals coming before it happened. He thinks Zambian copper junior Prospect has similar credentials.

QMines (ASX:QML) is consolidating its footprint with a new gold-silver opportunity at Mount Mackenzie in Queensland.

Strength in healthcare and financial stocks has kept the ASX on life support, retaining some gains to lift 0.21pc overall.

Meteoric Resources has been up to 36.3% higher after releasing a maiden resource estimate for the Bara do Pacu licence at its Caldeira REE project in Brazil.

Neuren Pharmaceuticals and its US partner Acadia have been blitzing it with the Rett syndrome treatment Daybue.

Graphene is gaining serious traction in Europe after major funding, while in Australia, Adisyn is positioning itself as a key ...

The US FDA has approved EBR System's leadless pacemaker WISE, the only heart device able to deliver left-ventricle ...

ASX nudges up on US tariff hopes, but Bellevue Gold gets hammered after a capital raise, while HUB24 shines with record inflows.